The patented Safe-2-Dose™ Integrated Dosing Container is the next generation Infants elixir dispenser providing enhanced medication dosing accuracy and user convenience. Th
Our Science
Asepsis is a medical device company specializing in the delivery enhancement of oral and parenteral medicinal solutions. Our core competence focuses on personalized dosed products that increase patient outcome and medication efficacy, by providing higher precision adherence to the established optimal clinical dosing.
The Asepsis portfolio enhances convenience and safety by providing health care professionals with intuitive delivery apparatus that simplify administration by the elimination of crucial user sequences. Our technology provides proprietary clinical and non-clinical enhancements that create innovative differentiated products, while in parallel continuing to conform to a medication’s original safety and efficacy profile.
Highest Standard of Care
Asepsis is dedicated to improving critical caregiver procedures and enhancing patient outcomes, through providing proprietary platforms that enable medications to be intuitively prepared and administered at the highest possible precision.
We are committed to transforming pediatric and personized dosed medicine to a higher standard of care by providing products that deliver medications precisely to their optimal therapeutic dose. Our portfolio can enhance patient outcomes across a broad range of medications in commercial use, and in most cases without any clinical trials or prior authorization required. Additionally, this personalized optimal dosing platform used within early drug trials, may also improve efficacy and/or reduce toxicity to individualized patients, thus potentially increasing the overall success of the drug candidate.
Injection Kits and Syringes
OTC and Rx Oral Elixir Dispensers
Emergency Self Injection Devices
Infusion Apparatus
Latest News
Asepsis Announces The Grant Of Mexico Patent No. 384,129
Asepsis Medical Technologies® is proud to introduce the latest addition to the Calibrated Drug Delivery™ (CCD) platform, the Multi-Dose Safe-2-Dose® syringe.
Asepsis Announces the Grant of Canadian Patent No. 3,006,218
Asepsis Medical Technologies® is proud to announce their latest Canadian Patent Grant 3,006,218 of August 24, 2021 – for the multi-dose oral Dose-2-Weight Syringe
Asepsis announces the US Patent Grant 11,058,606
Asepsis Medical Technologies announces the USPTO issuance of Patent Application Number 11,058,606 for its Safe-T-Fuse™ drug infusion system. The Safe-T-Fuse™ is an ind
Asepsis Announces the Grant of Mexico Patent MX/a/2017/012034
The Safe-T-Syringe® is designed to deliver the highest standard of patient care via syringe. Its medication calibrated indicia provide enhanced accuracy, convenience and sa
Asepsis Announces the Grant of U.S. Patent 10,857,299
Asepsis Medical Technologies® is proud to introduce the latest addition to the Calibrated Drug Delivery™ (CCD) platform, the Multi-Dose Safe-2-Dose® syringe. The Multi-Dose
Asepsis Announces the U.S. Patent Grant No. 10,625,026
Asepsis Medical Technologies announces the U.S. Patent Grant for the Momenta-Dose™ forcé actuated injection device. The Momenta Dose™ is designed to administer rapid small
Latest Media
Contact Us
Asepsis Medical Technologies, LLC
1584 Independence Boulevard
Sarasota, Florida 34234 USA
Tel: +1-941-360-0029
Fax: +1-941-360-0035
[email protected]
MÉXICO
La polar # 6, Col.Industrial
Mexico City, Mexico CP 07800
Tel: +52 (55) 5750-3516
Fax: +52 (55) 2789-5706
CHINA
12 F Merrit Industrial
Center Kowloon, Hong Kong
Tel: +852 9018 2393
Fax: +852 3010 1873
INDIA
226, Patel Center, Sainath
Road Malad West, Mumbai
Tel: +91 22 2844 2942
Fax: +91 22 6645 9822